Cargando…

Effectiveness of afatinib in an NSCLC patient with EGFR mutation and early progression to osimertinib: a case report

Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), shows great clinical activity in non-small cell lung cancer (NSCLC) patients with EGFR mutations regardless of T790M mutation at first-line chemotherapy. Previous studies demonstrated that there...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nozaki, Koichiro, Watanabe, Satoshi, Nishio, Kazuto, Sakai, Kazuko, Kikuchi, Toshiaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841509/ https://www.ncbi.nlm.nih.gov/pubmed/35261905 http://dx.doi.org/10.21037/tcr-21-1850

Ejemplares similares

Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib
por: Ishii, Hidenobu, et al.
Publicado: (2020)

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
por: Yamamoto, Nobuyuki, et al.
Publicado: (2019)

Is there a role for sequential afatinib and osimertinib in patients with EGFR mutation?
por: Iwamoto, Natsuhiko, et al.
Publicado: (2022)

The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells
por: Murakami, Yuichi, et al.
Publicado: (2017)

Hypothesis generative head-to-head study comparing efficacy of afatinib and osimertinib based on immunological biomarkers in Japanese NSCLC patients with EGFR mutations (Heat on Beat study)
por: Morikawa, Kei, et al.
Publicado: (2020)

Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib
por: Hochmair, Maximilian J., et al.
Publicado: (2018)

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
por: Zheng, Mei-Mei, et al.
Publicado: (2022)

Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review
por: Jiang, Yingying, et al.
Publicado: (2023)

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
por: Skrzypski, Marcin, et al.
Publicado: (2017)

Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
por: Jiang, Tao, et al.
Publicado: (2020)

Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations
por: Sato, Miyuki, et al.
Publicado: (2019)

Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC
por: Koyama, Kenichi, et al.
Publicado: (2022)

Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings
por: Harvey, R Donald, et al.
Publicado: (2020)

Afatinib and osimertinib in lung adenocarcinoma harbored EGFR T751_I759delinsS mutation: A case report
por: Fang, Yueh‐Fu, et al.
Publicado: (2021)

Afatinib + bevacizumab combination therapy in EGFR‐mutant NSCLC patients with osimertinib resistance: Protocol of an open‐label, phase II, multicenter, single‐arm trial
por: Kobayashi, Nobuaki, et al.
Publicado: (2020)

Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report
por: Liu, Jing, et al.
Publicado: (2019)

Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR ‐mutated NSCLC treated with afatinib
por: Wu, Chen‐Te, et al.
Publicado: (2023)

Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
por: Imamura, Fumio, et al.
Publicado: (2020)

Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation
por: Watanabe, Kana, et al.
Publicado: (2023)

Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report
por: Crowley, Fionnuala, et al.
Publicado: (2021)

Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
por: Lamb, Yvette N.
Publicado: (2021)

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
por: Ji, Jingran, et al.
Publicado: (2023)

Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy
por: Hayashi, Hidetoshi, et al.
Publicado: (2023)

High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib
por: Osoegawa, Atsushi, et al.
Publicado: (2021)

Significant Benefits of Afatinib and Apatinib in a Refractory Advanced NSCLC Patient Resistant to Osimertinib: A Case Report
por: Zhao, Yuanyang, et al.
Publicado: (2021)

Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
por: Lin, Ling, et al.
Publicado: (2020)

Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC
por: Cekay, Michael, et al.
Publicado: (2023)

Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report
por: Takakura, Toshiaki, et al.
Publicado: (2023)

Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
por: Takahashi, Akiko, et al.
Publicado: (2018)

Efficacy and safety of osimertinib in treating EGFR‐mutated advanced NSCLC: A meta‐analysis
por: Yi, Lilan, et al.
Publicado: (2019)

Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)
por: Bracht, Jillian Wilhelmina Paulina, et al.
Publicado: (2019)

Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
por: Lamb, Yvette N.
Publicado: (2021)

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience
por: Piper-Vallillo, A.J., et al.
Publicado: (2022)

Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation
por: Zöchbauer-Müller, Sabine, et al.
Publicado: (2021)

Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports
por: Li, Guangrui, et al.
Publicado: (2023)

Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report
por: Merkhofer, Cristina M., et al.
Publicado: (2021)

Incidence of Bone Metastases and Skeletal-Related Events in Patients With EGFR-Mutated NSCLC Treated With Osimertinib
por: Brouns, Anita J.W. M., et al.
Publicado: (2023)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Association of PD‐L1 tumor proportion score ≥20% with early resistance to osimertinib in patients with EGFR ‐mutated NSCLC
por: Hamakawa, Yusuke, et al.
Publicado: (2023)

Afatinib as a Potential Therapeutic Option for Patients With NSCLC With EGFR G724S
por: Wei, Yang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dpm3l8i1ur1vjeildqs2ok126e